| Budget Amount *help |
¥24,050,000 (Direct Cost: ¥18,500,000、Indirect Cost: ¥5,550,000)
Fiscal Year 2015: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2014: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2013: ¥12,220,000 (Direct Cost: ¥9,400,000、Indirect Cost: ¥2,820,000)
|
|---|
| Outline of Final Research Achievements |
In the present study, we designed IFNγ derivatives fused with a fibrin-binding pentapeptide (CREKA) for the development of effective IFNγ cancer gene therapy. We constructed plasmid DNA (pDNA) expressing an IFNγ-CREKA fusion protein and administered the pDNA into tumor-bearing mice by hydrodynamic injection. The fusion protein was detected to bind to fibrin clots in the tumor tissue. Moreover, tumor growth was suppressed by the administration of the pDNA. In conclusion, it was shown that IFNγ-CREKA fusion protein can be used to improve therapeutic effect of IFNγ cancer gene therapy.
|
